# Busulfan/Clofarabine + Allogeneic Stem Cell Transplantation

> **NCT01643668** · PHASE2 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 34 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Acute Lymphoblastic Leukemia
- Myelodysplastic Syndrome

## Interventions

- **DRUG:** Busulfan
- **DRUG:** Clofarabine
- **PROCEDURE:** Allogeneic Stem Cell Infusion

## Key facts

- **NCT ID:** NCT01643668
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2016-08
- **Final completion:** 2016-08
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2017-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01643668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01643668, "Busulfan/Clofarabine + Allogeneic Stem Cell Transplantation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01643668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*